Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 27, 2023

EMA accepts Eisai, Biogen’s lecanemab MAA for review to treat AD

The European Medicines Agency (EMA) has accepted for review Eisai and Biogen’s marketing authorization application (MAA) submitted for lecanemab to treat early Alzheimer’s disease (AD).

EMA accepts Eisai, Biogen’s lecanemab MAA for review to treat AD